Cardioprotective Effect of NSAIDs

Comment

Thomas Herdegen et al. Dtsch Arztebl Int. 2017.

. 2017 Aug 21;114(33-34):559.

doi: 10.3238/arztebl.2017.0559b.

No abstract available

Comment in

In Reply.
Braun J. Braun J. Dtsch Arztebl Int. 2017 Aug 21;114(33-34):560. doi: 10.3238/arztebl.2017.0560b. Dtsch Arztebl Int. 2017. PMID: 28855051 Free PMC article. No abstract available.

Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions.
Braun J, Krüger K, Manger B, Schneider M, Specker C, Trappe HJ. Braun J, et al. Dtsch Arztebl Int. 2017 Mar 24;114(12):197-203. doi: 10.3238/arztebl.2017.0197. Dtsch Arztebl Int. 2017. PMID: 28407841 Free PMC article. Review.

1. Braun J, Krüger K, Manger B, Schneider M, Specker C, Trappe HJ. Cardiovascular comorbidity in inflammatory rheumatological conditions. Dtsch Arztebl Int. 2017;114:197–203. - PMC - PubMed
1. Roubille C, Richter V, Starnino T, et al. The effects of tumor necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480–489. - PMC - PubMed
1. Zingler G, Hermann B, Fischer T, Herdegen T. Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks. Expert Rev Clin Pharmacol. 2016;9:1479–1492. - PubMed
1. Goodson NJ, Brookhart AM, Symmons DP, et al. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis. 2009;68:367–372. - PMC - PubMed